Personalis (NASDAQ:PSNL) Given “Buy” Rating at BTIG Research

BTIG Research restated their buy rating on shares of Personalis (NASDAQ:PSNL) in a report issued on Friday morning,Benzinga reports. They currently have a $12.00 price objective on the stock.

Other analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. Morgan Stanley raised their price target on shares of Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a report on Monday, December 1st. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. HC Wainwright increased their price target on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $10.57.

Personalis Price Performance

NASDAQ PSNL opened at $8.10 on Friday. The company has a market capitalization of $719.28 million, a P/E ratio of -9.20 and a beta of 1.96. Personalis has a 1-year low of $2.83 and a 1-year high of $11.40. The business has a 50 day moving average price of $8.72 and a 200 day moving average price of $7.26.

Personalis (NASDAQ:PSNL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The firm had revenue of $14.50 million for the quarter, compared to analysts’ expectations of $13.31 million. On average, research analysts expect that Personalis will post -1.4 earnings per share for the current fiscal year.

Insider Buying and Selling at Personalis

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the completion of the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This represents a 38.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher M. Hall sold 29,612 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the completion of the transaction, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. This trade represents a 16.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Royal Bank of Canada grew its stake in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares during the last quarter. Howland Capital Management LLC lifted its holdings in Personalis by 0.9% during the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after acquiring an additional 2,500 shares in the last quarter. Legal & General Group Plc bought a new stake in Personalis during the 2nd quarter worth approximately $30,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Personalis during the second quarter worth $34,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the period. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.